These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 15942243)

  • 21. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
    Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S
    J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pro-MMP-9/TIMP-1 ratio correlates poorly with a direct assessment of MMP-9 activity.
    Tarr GP; Williams MJ; Phillips LV; van Rij AM; Jones GT
    Clin Biochem; 2011 Dec; 44(17-18):1480-2. PubMed ID: 22020222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis.
    Ichiyama T; Siba P; Suarkia D; Takasu T; Miki K; Kira R; Kusuhara K; Hara T; Toyama J; Furukawa S
    J Neurol Sci; 2007 Jan; 252(1):45-8. PubMed ID: 17118404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus.
    Robak E; Wierzbowska A; Chmiela M; Kulczycka L; Sysa-Jedrejowska A; Robak T
    Mediators Inflamm; 2006; 2006(1):17898. PubMed ID: 16864898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seasonal variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor of matrix metalloproteinase-1 with storage at -80°C.
    Tarr GP; Williams MJ; Phillips LV; van Rij AM; Jones GT
    Clin Biochem; 2011 Nov; 44(16):1346-8. PubMed ID: 21939646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating matrix metalloproteinases and their inhibitors in inguinal hernia and abdominal aortic aneurysm.
    Antoniou GA; Tentes IK; Antoniou SA; Georgiadis GS; Giannoukas AD; Simopoulos C; Lazarides MK
    Int Angiol; 2011 Apr; 30(2):123-9. PubMed ID: 21427648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix metalloproteases and their tissue inhibitor in cardiac transplantation.
    Aharinejad S; Krenn K; Zuckermann A; Schäfer R; Paulus P; Seebacher G; Wolner E; Grimm M
    Eur J Cardiothorac Surg; 2007 Jul; 32(1):48-51. PubMed ID: 17482473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
    ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
    Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
    Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smoking and matrix metalloproteinases, neutrophil elastase and myeloperoxidase in chronic periodontitis.
    Ozçaka O; Biçakci N; Pussinen P; Sorsa T; Köse T; Buduneli N
    Oral Dis; 2011 Jan; 17(1):68-76. PubMed ID: 20646231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study.
    Babić T; Mahović Lakusić D; Sertić J; Petrovecki M; Stavljenić-Rukavina A
    Coll Antropol; 2004 Jun; 28(1):199-204. PubMed ID: 15636076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
    Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
    Karabudak R; Kurne A; Guc D; Sengelen M; Canpinar H; Kansu E
    J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.